Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CCR4 | P51679 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419211 | 0.90 | RXFP1 (0.70) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL2425236 | 0.87 | RXFP1 (0.71) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL2421801 | 0.85 | RXFP1 (0.72) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL2304579 | 0.83 | RXFP1 (0.79) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL10044455 | 0.82 | RXFP1 (0.68) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL2418454 | 0.81 | RXFP1 (1.00) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL10044457 | 0.81 | RXFP1 (0.71) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL189044 | 0.81 | RXFP1 (1.00) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL4682254 | 0.80 | RXFP1 (0.57) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 | |
| SCHEMBL27748999 | 0.80 | RXFP1 (0.64) | RXFP1ALDH1A1L3MBTL1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2374802-B1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2630130-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | Merck Serono S.A. Geneva (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | RXFP1 4100/4885ALDH1A1 1531/4885L3MBTL1 1118/4885 |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | STS, NQO2, ASNS | RXFP1 3539/4885ALDH1A1 2918/4885L3MBTL1 4853/4885 |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | CCR5, CCR4, CCR1 | RXFP1 433/4885ALDH1A1 2497/4885L3MBTL1 2983/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | RXFP1 433/4885ALDH1A1 2497/4885L3MBTL1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.